Oseltamivir

CHEMBL1229 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

6-10 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

312.4 g/mol

LogP

1.1

Phase

4

An antiviral neuraminidase inhibitor for treating and preventing influenza, most effective within 48 hours.

น้ำหนักโมเลกุล

312.4050 g/mol

LogP

1.10

TPSA

90.70 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Respiratory Disease Pain Management Asthma Chronic Obstructive Pulmonary Disease Insomnia Gastroesophageal Reflux Disease Systemic Lupus Erythematosus Obesity Hypertension Chronic Pain Heart Failure

หมวดหมู่ยา

J — J - Antiinfectives for Systemic Use

กลไกการออกฤทธิ์

Neuraminidase inhibitor preventing viral release from host cells.

Pharmacokinetics (PK)

Half-Life 6-10 hours

Pharmacodynamics (PD)

กลไก

Neuraminidase inhibitor preventing viral release from host cells.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

InChI

InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1

Molecular Formula

C16H28N2O4

HBD / HBA

2 / 5

พันธะที่หมุนได้

8

อะตอมหนัก

22

ABCB1 (P-glycoprotein) Substrate

Primary Target

Minor Oseltamivir + Warfarin

Oseltamivir does not appear to meaningfully alter warfarin pharmacokinetics; however, the febrile illness being treated may independently elevate INR, which can be mistakenly attributed to the antiviral.

Minor Oseltamivir + Methotrexate

Both oseltamivir carboxylate and methotrexate rely on renal tubular secretion via OAT transporters; theoretically, competition could reduce elimination of either drug, though clinical evidence of a significant interaction is limited.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An antiviral neuraminidase inhibitor for treating and preventing influenza, most effective within 48 hours.

Neuraminidase inhibitor preventing viral release from host cells.

Key pharmacokinetic parameters for Oseltamivir: Half-life: 6-10 hours.

Yes, Oseltamivir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

ADME Journey →

Related Drugs

Same Drug Class

Amoxicillin Small molecule Azithromycin Small molecule Ciprofloxacin Small molecule Doxycycline Small molecule

Same Target

Aspirin Small molecule Metformin Small molecule Atorvastatin Small molecule Omeprazole Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1229. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 65028. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Oseltamivir บน PillFYI

โครงสร้าง

ข้อมูลด่วน

Class: J - Antiinfectives for Systemic Use
สูตร: C16H28N2O4
คำพ้องความหมาย: 3

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Oseltamivir

ด้านการรักษา

หมวดหมู่ยา

กลไกการออกฤทธิ์

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

Cite this structure

Embed this structure

No side effects recorded

คำถามที่พบบ่อย

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget